-
Presenter Perspectives: Racial Disparities in Amputation Outcomes—Making the Difference
Foluso A. Fakorede, MD, shares details about this presentation, which begins Monday, June 28, at 9:30 a.m. ET.
-
Presenter Perspectives: Stromal Engagement in Adipose—Adipogenesis vs. Fibrosis
Rana K. Gupta, PhD, shares details about this presentation, which begins Monday, June 28, at 9:30 a.m. ET.
-
Presenter Perspectives: Inpatient Use of Hybrid Closed-Loop Systems
Joseph Aloi, MD, shares details about this presentation, which begins Monday, June 28, at 9:36 a.m. ET.
-
Presenter Perspectives: Clinical Inertia—Treatment Deintensification
Rajesh Garg, MD, shares details about this presentation, which begins Monday, June 28, at 12:20 p.m. ET.
-
Presenter Perspectives: Food Is Medicine for People with Diabetes and At-Risk of Diabetes
Guoxun Chen, PhD, shares details about this presentation, which begins Monday, June 28, at 4:30 p.m. ET.
-
Presenter Perspectives: Omics and Interferon/Cytokine Responses in Type 1 Diabetes
Lorenzo Pasquali, MD, PhD, shares details about this presentation, which begins Tuesday, June 29, at 9:00 a.m. ET.
-
Presenter Perspectives: Diet as Both Cause and Intervention for Cancer
Marcus D. Goncalves, MD, PhD, shares details about this presentation, which begins Tuesday, June 29, at 9:30 a.m. ET.
-
Presenter Perspectives: Disparity of Risk for Impaired Awareness of Hypoglycemia and Severe Hypoglycemia—Exploring the Human Situation
Amir Moheet, MBBS, shares details about this presentation, which begins Friday, June 25, at 1:15 p.m. ET.
-
Researchers will provide new data from SCORED and SOLOIST trials
A combined SGLT1/SGLT2 inhibitor may be the next addition to the armamentarium of drugs for patients with diabetes. Deepak Bhatt, MD, MPH, will explain why and take a comprehensive look at data from recent clinical trials of sotagliflozin.
-
Investigators to share first cardiovascular outcomes results from AMPLITUDE-O
Hertzel C. Gerstein, MD, MSc, FRCPC, will offer insight into the use of an exendin-based GLP-1 receptor agonist in people with type 2 diabetes and high cardiovascular risk.